Our Company

Partnering

Partnering Opportunities

At Dicerna, we believe that strategic partnerships, research collaborations and licensing arrangements should add value to both parties, assisting each in attaining goals beyond those that could be achieved individually. Dicerna’s GalXC™ RNAi technology platform supports our long-term strategy to retain a full or substantial ownership stake and invest internally for diseases with focused patient populations, such as certain rare diseases, as we see such diseases as representing opportunities that carry high probabilities of success, have easily identifiable patient populations and a limited number of Centers of Excellence to facilitate reaching these patients, and have the potential for more rapid clinical development programs. For more complex diseases with multiple gene dysfunctions and larger patient populations, we plan to pursue partnerships that can provide the enhanced scale, resources and commercial infrastructure required to maximize these prospects.

Our ideal industry partners help us to more efficiently use our proprietary RNAi technology platform to build a broad pipeline of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral infectious diseases. Tactical collaborations with other industry leaders allow us to maximize the potential of our programs to promote faster and more efficient development. Through these partnerships, we will advance product development and commercialization, leading to the availability of new therapies.

The Dicerna team is eager to discuss collaborative opportunities utilizing our RNAi platform across multiple indication areas.

Please contact Jim Weissman, Chief Operating Officer and Executive Vice President, at (617) 612-6214 or jweissman@dicerna.com regarding the company’s partnering strategy.

 

Current Partnerships

 

Dicerna entered into an agreement with Novo Nordisk to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases. Dicerna will conduct and fund discovery and preclinical development to clinical candidate selection for each liver cell target, and Novo Nordisk will be responsible for all further development.* Visit website.

 


 

Dicerna entered into a research collaboration and licensing agreement with Roche to develop novel therapies for the treatment of chronic hepatitis B virus (HBV) infection using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration will focus on worldwide development and commercialization of DCR-HBVS, Dicerna’s investigational therapy in Phase 1 clinical development. The collaboration also includes the discovery and development of therapies targeting multiple additional human and viral genes associated with HBV infection using the technology platforms of both companies.* View website.

 


 

Dicerna has a global licensing and research collaboration with Eli Lilly and Company focused on the discovery, development, and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration, and pain. The companies will utilize Dicerna’s GalXC platform to progress new drug targets toward clinical development and commercialization. In addition, the partners will collaborate to move beyond the current technical paradigm in order to generate next-generation oligonucleotide therapeutic agents. The two companies anticipate collaborating on more than ten targets. View website.

 


 

Dicerna and Alexion Pharmaceuticals, Inc. are collaborating to discover and develop RNAi therapies for complement-mediated diseases. The agreement provides Alexion with exclusive worldwide licenses as well as development and commercial rights for two of Dicerna’s preclinical, subcutaneously delivered GalXC molecules and an exclusive option for other preclinical GalXC molecules for two additional targets within the complement pathway. Dicerna will lead the joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with Phase 1 studies.  The agreement provides Alexion with exclusive worldwide licenses and commercial rights to the GalXC RNAi molecules developed in the collaboration. View website.

 


 

Dicerna entered into a collaborative research and license agreement with Boehringer Ingelheim International GmbH (BI) to jointly research and develop product candidates for the treatment of chronic liver diseases, with an initial focus on nonalcoholic steatohepatitis (“NASH”) using our GalXC platform. The agreement is for the development of product candidates against one target gene with an option for BI to add the development of product candidates that target a second gene. Dicerna is responsible for the discovery and initial profiling of the product candidates, including primary pre-clinical studies, synthesis, and delivery. BI is responsible for evaluating and selecting the product candidates for further development and will be responsible for further pre-clinical development, clinical development, manufacturing and commercialization of those products. View website.

 

* Novo Nordisk A/S and Roche transactions are subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions.